This is a working overview of thymosin beta-4 fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-23. Anything still debated is marked as such rather than presented as settled.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
== Mechanism of catalysis == The molecular mechanism of O-linked N-acetylglucosamine transferase has not been extensively studied either, since there is not a confirmed crystal structure of the enzyme. A proposed mechanism by Lazarus et al. is supported by product inhibition patterns of UDP at saturating peptide conditions. This mechanism proceeds with starting materials Uridine diphosphate N-acetylglucosamine, and a peptide chain with a reactive serine or threonine hydroxyl group. The proposed reaction is an ordered sequential bi-bi mechanism.
Contamination has also been seen in water wells and other sources of drinking water. This contamination is seen in US, United Kingdom, Germany, Japan, and Canada, but information from most developing countries is nearly nonexistent. The lack of information on PFAS contamination in developing countries, especially those in Africa, are due to structural socioeconomic inequality and lack of access to the expensive laboratory capabilities required for PFAS quantification.
=== 18 April === Two people were killed in separate Russian attacks in Donetsk Oblast. Russia claimed to have shot down five Ukrainian balloons carrying explosives over Belgorod and Voronezh Oblasts. A Polish national was arrested in Poland on suspicion of spying for Russia as part of a plot to assassinate Zelenskyy during his visit there, following a tip from Ukrainian authorities. EU foreign policy chief Josep Borrell called on EU member states to send anti-missile systems to Ukraine.
== History == Phytochelatin was first discovered in 1981 in fission yeast, and was named cadystin. It was then found in higher plants in 1985 and was named phytochelatin. In 1989 the biosynthetic enzyme, phytochelatin synthase, was discovered.
== Mechanism of action == The exact mechanism of action of silicone gel sheeting has not been fully studied. Currently, many proposed mechanisms explain the efficacy of such treatment, including the occlusion and hydration effect, increased body surface temperature, polarized electric charge, immunological effects, etc. The occlusion and hydration effect is the most studied mechanism of action.
Sources: en.wikipedia.org
Intraocular pressure can sometimes reach 80 mmHg (11 kPa). It characteristically manifests as ciliary body inflammation and massive trabecular edema that sometimes extends to Schlemm's canal. This condition is differentiated from malignant glaucoma by the presence of a deep and clear anterior chamber and a lack of aqueous misdirection. Also, the corneal appearance is not as hazy. A reduction in visual acuity can occur, followed by neuroretinal breakdown.
=== On nuclear factor kappa B === Certain poloxamers such as P85 have been shown not only to be able to transport target genes to target cells, but also to increase gene expression. Certain poloxamers, such as P85 and L61, have also been shown to stimulate transcription of NF kappaB genes, although the mechanism by which this is achieved is currently unknown, bar that P85 has been shown to induce phosphorylation of the inhibitory kappa.
== Clinical pharmacology == Although the drugs omeprazole, lansoprazole, pantoprazole, and rabeprazole share common structure and mode of action, each differs somewhat in its clinical pharmacology. Differing pyridine and benzimidazole substituents result in small, but potentially significant different physical and chemical properties. Direct comparison of pantoprazole sodium with other anti-secretory drugs showed that it was significantly more effective than H2-receptor antagonists and either equivalent or better than other clinically used PPIs. Another study states rabeprazole undergoes activation over a greater pH range than omeprazole, lansoprazole, and pantoprazole, and converts to the sulphenamide form more rapidly than any of these three drugs. Most oral PPI preparations are enteric-coated, due to the rapid degradation of the drugs in the acidic conditions of the stomach. For example omeprazole is unstable in acid with a half-life of 2 min at pH 1–3, but is significantly more stable at pH 7 (half-life ca. 20 h). The acid protective coating prevents conversion to the active principle in the lumen of the stomach, which then will react with any available sulfhydryl group in food and will not penetrate to the lumen of the secretory canaliculus The oral bioavailability of PPIs is high; 77% for pantoprazole, 80–90% for lansoprazole and 89% for esomeprazole. All the PPIs except tenatoprazole are rapidly metabolized in the liver by CYP enzymes, mostly by CYP2C19 and CYP3A4. PPIs are sensitive to CYP enzymes and have different pharmacokinetic profiles.
Dark and old soy sauce (老抽; pinyin: lǎo chōu; Jyutping: lou5 cau1; Cantonese Yale: lóuhchāu), a darker and slightly thicker soy sauce made from light soy sauce. This soy sauce is made through prolonged aging and may contain added caramel colour or molasses to give it its distinctive appearance. It has a richer, slightly sweeter, and less salty flavour than light soy sauce. This variety is mainly used during cooking, since its flavour develops during heating. Dark soy sauce is mainly used to add color and flavor to a dish after cooking. One of the strongest varieties is known as "double black" (雙老頭抽) Mushroom dark soy (草菇老抽 cǎogū lǎochōu): In the finishing and aging process of making dark soy sauce, the broth of Volvariella volvacea (straw mushroom) is mixed into the soy sauce and is then exposed to the sun to make this type of dark soy. The added broth gives this soy sauce a richer flavor than plain dark soy sauce. Thick soy sauce (醬油膏 jiàng yóu gāo) is a dark soy sauce that has been thickened with heat and sugar; occasionally a starch thickener and MSG are used. This sauce is often used as a dipping sauce or finishing sauce and poured on food as a flavorful addition. However, due to its sweetness and caramelized flavors from its production process, the sauce is also used in red cooking. This style is particularly common with Taiwanese breakfast foods. Shrimp soy sauce (蝦子醬油 xiā zǐ jiàngyóu): Fresh soy sauce is simmered with fresh shrimp and finished with sugar, baijiu (a type of distilled liquor, 白酒), and spices. It is a specialty of Suzhou.
Sources: en.wikipedia.org
The game included a brawl shortly after half time sparked by Essendon's captain Matthew Lloyd knocking out Hawthorn midfielder Brad Sewell, which led Hawthorn's Campbell Brown, to label Lloyd a 'sniper', and promised revenge if Lloyd played on in 2010. North Melbourne – One of the fiercest rivalries in the AFL can be traced back to 1896, when several clubs, including Essendon, broke away from the Victorian Football Association to form the Victorian Football League. North sought to join the breakaway competition, but some argue this desire was not realised due to Essendon feeling threatened by North's proximity and the fact their inclusion could drain Essendon of vital talent. More than 100 years later, some North supporters have not forgiven Essendon for the decision and have blamed the Bombers for their small supporter base and gate revenue. North were finally admitted into the VFL in 1925 alongside Footscray and Hawthorn. In 1950, the two sides met in their first and only grand final meeting to date, which Essendon won by 38 points. The rivalry would flare up again in the 1980s. In 1982, the Krakouer brothers, Jim and Phil, led the Roos to an Elimination Final win. Essendon had their revenge a year later, winning a Preliminary Final by 86 points. The rivalry was re-ignited in the late 1990s and early 2000s due to the on-field success of the two sides.
== Ligand selection == Ligands are molecules responsible for binding to receptors in the cellular targeting process. Surface-coupled ligands offer a greater degree of freedom to move on the liposome membrane for optimal interactions. Ligands are typically monoclonal antibodies (mAbs) or antibody fragments, but can also include other molecules such as ARPG, proteins, peptides, vitamins, carbohydrates, and glycoproteins. The choice of ligand can significantly influence the behavioral and functional properties of a ligand-targeted liposome. Antibody fragments have lower immunogenicity and improved pharmacokinetics. mAbs are unique and can be used for inhibition of DNA repair, terminating the cell cycle, and triggering apoptosis, all of which factor into applications for anticancer drugs. Peptides are relatively easy and affordable to prepare with low antigenicity and lower opsonization, which are thus more resistant to enzymatic degradation. Proteins can target the transferrin receptor membrane glycoprotein. Sugars and vitamins are recognized by cellular transport receptors. Ligand choice is based on receptor expression, ligand internalization, binding affinity, and type of ligand. Ligands alone are not able to carry an efficient payload for therapeutic levels but can carry more of the agent when combined with liposomes.
Additional evidence supporting the concept of an RNA world has resulted from research on viroids, the first representatives of a novel domain of "subviral pathogens". Viroids infect plants, where most are pathogens, and consist of short stretches of highly complementary, circular, single-stranded and non-coding RNA without a protein coat. They are extremely small, ranging from 246 to 467 nucleobases, compared to the smallest known viruses capable of causing an infection, with genomes about 2,000 nucleobases in length. Based on their characteristic properties, in 1989 plant biologist Theodor Diener argued that viroids are more plausible living relics of the RNA world than introns and other RNAs considered candidates at the time. Diener's hypothesis would be expanded by the research group of Ricardo Flores, and gained a broader audience when in 2014, a New York Times science writer published a popularized version of the proposal. The characteristics of viroids highlighted as consistent with an RNA world were their small size, high guanine and cytosine content, circular structure, structural periodicity, the lack of protein-coding ability and, in some cases, ribozyme-mediated replication. One aspect critics of the hypothesis have focused on is that the exclusive hosts of all known viroids, angiosperms, did not evolve until billions of years after the RNA world was replaced, making viroids more likely to have arisen through later evolutionary mechanisms unrelated to the RNA world than to have survived via a cryptic host over that extended period.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.